{"id":"NCT00686790","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)","officialTitle":"An Open Label, Uncontrolled, Study to Assess the Response of Peg-Intron in na√Øve Patients With Chronic Hepatitis B and D Co-infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2008-05-30","resultsPosted":"2011-01-17","lastUpdate":"2017-04-06"},"enrollment":68,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis D, Chronic","Hepatitis B, Chronic"],"interventions":[{"type":"BIOLOGICAL","name":"Peginterferon alfa-2b (PegIntron, SCH 54031)","otherNames":["SCH 54031, PegIntron"]}],"arms":[{"label":"PegIntron","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to determine the effectiveness of peginterferon alfa-2b 1.5 mcg/kg/week administered for 52 weeks (wk) in previously untreated participants coinfected with hepatitis virus B and D. After 52-week treatment and 52-week follow-up, the virologic, biochemical, and histological response will be evaluated.","primaryOutcome":{"measure":"Number of Participants With a Virological Response","timeFrame":"52 weeks (end of treatment [EOT]), 104 weeks (end of follow-up [EOF]) following treatment initiation","effectByArm":[{"arm":"PegIntron","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":49},"commonTop":["PYREXIA","HEADACHE","CHILLS","MYALGIA","FATIGUE"]}}